Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

01 January 2009

Plasma complement 3d levels in the early phase after pancreas transplantation

Angela Suermann, Oliver Vonend, Peter Schenker, Richard Viebahn, Lars C. Rump, Stefan M. Weiner

Ann Transplant 2009; 14(3): 29-35 :: ID: 880538

Abstract

Background: Rejection and graft thrombosis are the main reasons leading to early graft loss after pancreas transplantation. Identifying parameters that forecast these complications would be helpful. Complement activation might occur during rejection and thrombosis leading to elevated complement split products. This prospective study analyses the plasma complement 3d (C3d) levels in the early post-pancreas transplant (PTx) period to test its predictive value to determine rejection and thrombosis.
Material/Methods: Plasma C3d levels were measured after isolated PTx (n=2), simultaneous pancreas and kidney transplantation (SPKT, n=20) and pancreas re-transplantation (n=3).
Results: Pancreas rejection was observed in 3, pancreas thrombosis in 4, and kidney rejection in 7 patients. Patients after isolated kidney transplantation (IKT) served as controls. Within 40 days after PTx and IKT C3d levels were significantly elevated compared to volunteers and long-term kidney transplant recipients (p<0.001). C3d levels increased during 40 days after PTx, but dropped after IKT. During pancreas rejection episodes mean C3d levels were elevated (14.0±3.5 mg/l) compared to those obtained during graft thrombosis (9.1±1.6 mg/l; p=0.012) or periods of normal graft function (10.6±1.9 mg/l; p=0.046). A slight elevation of C3d was observed during kidney rejection episodes in SPKT (12.7±2.0 mg/l; p=0.074) but not during kidney rejection after IKT.
Conclusions: C3d plasma levels increase during episodes of pancreas rejection and decrease in pancreas transplant thrombosis. However, single C3d values have no predictive diagnostic value after SPKT.

Keywords: Complement 3d

Add Comment 0 Comments

In Press

Original article  

Diagnostic Utility of FAR1 Methylation Levels in Hepatocellular Carcinoma Patients Undergoing Liver Transpl...

Ann Transplant In Press; DOI: 10.12659/AOT.951568  

Original article  

Inferior Long-Term Outcome of Fatty Liver Allografts After Orthotopic Liver Transplantation

Ann Transplant In Press; DOI: 10.12659/AOT.950589  

Database Analysis  

Identification and Validation of Liver Transplantation-Induced Acute Lung Injury Biomarkers Using a Bioinfo...

Ann Transplant In Press; DOI: 10.12659/AOT.950289  

Original article  

Survival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellula...

Ann Transplant In Press; DOI: 10.12659/AOT.950997  

Most Viewed Current Articles

24 Aug 2021 : Review article   18,372

Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future Perspectives

DOI :10.12659/AOT.931664

Ann Transplant 2021; 26:e931664

05 Apr 2022 : Original article   14,731

Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver Transplantation

DOI :10.12659/AOT.935604

Ann Transplant 2022; 27:e935604

22 Nov 2022 : Original article   14,244

Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...

DOI :10.12659/AOT.937988

Ann Transplant 2022; 27:e937988

29 Dec 2021 : Original article   13,752

Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...

DOI :10.12659/AOT.933588

Ann Transplant 2021; 26:e933588

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358